Affymetrix AFFX today announced that it has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA) to market its
CytoScan® Dx Assay. This assay is intended for the postnatal
detection of DNA copy number variants (CNV) in patients referred for
chromosomal testing. CytoScan Dx Assay is designed to help physicians
diagnose children's developmental and intellectual disabilities more
comprehensively by enabling a high-resolution genome-wide analysis of
genetic aberrations. High resolution analysis can reveal small
aberrations not readily seen using traditional techniques.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in